REAL AD DAY 2026 – Research progress, community, and what lies ahead
May 5, 2026On April 24, we continued last year’s tradition by celebrating the second anniversary of the REAL AD study and recognizing the participants who make it all possible. The afternoon was dedicated to sharing updates on study progress and highlighting recent advances in Alzheimer’s disease research.
The program began with talks from our study lead and research team, including physicians and neuropsychologists. Key topics included the role of blood-based biomarkers in research and the use of digital cognitive testing, presented by Dr. Joel Simrén and Dr. Fredrik Öhman. Our study lead, Professor Michael Schöll, also shared preliminary findings from the REAL AD screening study and outlined plans for the ongoing validation sub-study.
After the break, conversations with representatives from organizations such as Närhälsan and the Alzheimer’s Foundation followed, helping contextualise current research into a wider framework. An update was provided on newly developed therapies (including Leqembi) and their approval status across countries.
It was a day defined by reciprocity, warmth, and plenty of fika - an ideal way to celebrate this milestone. We would like to reiterate our sincere gratitude for our participants’ commitment and support as we continue this journey together. Thank you for being such an engaged and inspiring community.
